Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1653 1654 1658 1675
This examiner grants 80% of resolved cases
Archana Varadaraj operates in Art Unit 1636 of Tech Center 1600 and has handled 5 resolved cases. The data shows a high allowance rate of 80.0%, though this is based on a very limited number of outcomes. Successful applications reach a grant with a median days to allowance of 1263, which serves as the primary timeline indicator for the 5 resolved cases. While the success rate is high, the duration of prosecution suggests that cases may undergo multiple rounds of examination before reaching a final resolution.
The interview lift is notably high at 33.3%, suggesting that direct communication is extremely effective even when the baseline allowance rate is already 80.0%. However, practitioners should be mindful that these figures are derived from only 5 resolved cases, which may not yet represent a long-term trend. The 1263-day median pendency suggests that while success is likely, the process requires a significant time investment. Interviews appear to be a strong strategic choice to ensure a positive result and potentially clarify technical issues that contribute to the long pendency. As the examiner resolves more cases, these metrics will provide a clearer picture of the typical prosecution experience in Art Unit 1636.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18468937 | METHOD FOR PRODUCING AMINO ACID OR PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND COMPOUND | Non-Final OA | FUJIFILM Corporation |
| 18690563 | Prodrugs of Antibiotic Teixobactin | Non-Final OA | The Regents of the University of California |
| 18541815 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | Non-Final OA | Ohio State Innovation Foundation |
| 18460519 | FLUORINATED FIBERS FOR MULTIMODAL 1H AND 19F MRI, ULTRASOUND, FLUORESCENCE DETECTION AND CONFORMATIONAL AND TEMPERATURE DETECTION BY 19F MRS | Non-Final OA | New York University |
| 18223327 | METHODS FOR TREATING GRAFT-VERSUS-HOST DISEASE USING GLP-2 AGONISTS AND ANALOGUES THEREOF | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18707072 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PAIN, COMPRISING GR82334 AS ACTIVE INGREDIENT | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18761250 | DIAGNOSIS AND TREATMENT OF VASODILATORY SHOCK | Non-Final OA | University Of Maryland, Baltimore |
| 18331331 | HIDDEN ANTIBIOTICS IN THE HUMAN PROTEOME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18286816 | ANTI-VIRAL PEPTIDE COMPOSITIONS AND METHODS TO IMPROVE BIOLOGICAL ACTIVITY THEREOF | Non-Final OA | NANYANG TECHNOLOGICAL UNIVERSITY |
| 18422556 | METHODS OF TREATING TRAUMATIC BRAIN INJURY AND RELATED NEUROLOGICAL CONDITIONS | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | Non-Final OA | Oregon Health & Science University |
| 18310733 | GLUCAGON DELIVERY VIA ENZYMATIC ACTUATION | Final Rejection | University of Notre Dame du Lac |
| 17614231 | EFFICIENT METHOD FOR PREPARING PPR PROTEIN AND USE OF THE SAME | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18277220 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18253146 | EXTREMELY FAST SOLID PHASE SYNTHESIS | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 18299620 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy